Growth of metastatic triple negative breast cancer is inhibited by deep tumor-penetrating and slow tumor-clearing chemotherapy: the case of tumor adhering liposomes with interstitial drug release.
The poor prognosis of Triple Negative Breast Cancer (TNBC) is attributed largely to the lack of tumor selective therapeutic modalities that effectively deliver lethal doses at the sites of metastatic disease. Tumor-selective drug delivery strategies that aim to improve uniformity in intratumoral drug microdistributions and to prolong exposure of these cancer cells to delivered therapeutics may improve efficacy against established TNBC metastases. In this study, we present lipid carriers for selective (due to their nanometer size) tumor delivery which are loaded with cisplatin and are designed to exhibit the following properties when in the tumor interstitium: 1) interstitial drug release (for deeper tumor penetration of cisplatin) and/or 2) intratumoral/interstitial adhesion of the carriers to tumors' extracellular matrix (ECM) - not accompanied by cell internalization - for delayed tumor clearance of carriers prolonging cancer cell exposure to the cisplatin being released. We show that on large multicellular spheroids, used as surrogates of avascular solid tumor regions, greater efficacy was strongly correlated with spatially more uniform drug concentrations (due to interstitial drug release) and with higher time-integrated drug concentrations (enabled by slow clearing nanocarriers due to adhesion to the ECM ). Lipid nanocarriers with both the release and adhesion properties were the most effective, followed by nanocarriers with only the releasing property, and then by nanocarriers with only the adhering property. In vivo, cisplatin-loaded nanocarriers with the releasing and/or the adhering properties significantly inhibited the growth of spontaneous TNBC metastases, and the efficacy of different properties' combinations followed the same trends as in spheroids. This study demonstrates the therapeutic potential of a general strategy to bypass treatment limitations of TNBC established metastases due to lack of cell-targeting markers: aiming to optimize the temporal intratumoral drug microdistributions for more uniform and prolonged drug exposure.